What is Parallel Bio?
Parallel Bio is revolutionizing drug discovery by integrating advanced organoid technology with artificial intelligence to construct highly accurate models of human biology. Their proprietary platform is capable of replicating the human immune system across diverse populations, enabling unprecedented speed and precision in predicting drug efficacy and identifying novel disease targets, surpassing the limitations of traditional animal models. Pharmaceutical giants, including three Fortune 500 entities, are leveraging Parallel Bio's 'Clinical Trial in a Dish' to rigorously assess the safety and effectiveness of immunotherapies. Established in 2021 by two scientists renowned for developing the world's first scalable human immune organoid, the company is headquartered in Cambridge, Massachusetts.
How much funding has Parallel Bio raised?
Parallel Bio has raised a total of $25.3M across 2 funding rounds:
Angel/Seed
$4.3M
Series A
$21M
Angel/Seed (2022): $4.3M with participation from Y Combinator, Breakout Ventures, and Refactor Capital
Series A (2025): $21M led by Amplo, Atypical Ventures, Undeterred Capital, AIX Ventures, and Metaplanet
Key Investors in Parallel Bio
Y Combinator
Y Combinator, a prominent accelerator founded in 2005, provides crucial seed funding and guidance to early-stage startups, playing a vital role in nurturing nascent businesses.
Breakout Ventures
Breakout Ventures is a venture capital firm dedicated to investing in transformative companies driven by scientific innovation and technology, with a focus on creating new markets and scaling scientific advancements.
Amplo
Amplo is a global venture capital firm that supports entrepreneurs in building ambitious companies, with a strategic focus on innovative startups across sectors like financial services and healthcare, including notable investments in Robinhood and Parsley Health.
What's next for Parallel Bio?
With the infusion of major strategic investment, Parallel Bio is poised to accelerate its mission of transforming drug development. The substantial capital raised, particularly the recent $21M, will likely fuel further platform enhancement, expansion of research collaborations with pharmaceutical partners, and scaling of operations. This significant backing suggests a transition towards broader clinical validation and commercialization efforts, solidifying Parallel Bio's position as a key innovator in predictive biological modeling and a critical player in the future of pharmaceutical research and development.
See full Parallel Bio company page
